X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse ALEMBIC PHARMA with TEVA PHARMACEUTICAL INDUSTRIES LTD. - Israel - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALEMBIC PHARMA vs TEVA PHARMA (Israel) - Comparison Results

TEVA PHARMA (Israel)
   Change

Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 ALEMBIC PHARMA   TEVA PHARMA
EQUITY SHARE DATA
    ALEMBIC PHARMA
Mar-18
TEVA PHARMA
Dec-13
ALEMBIC PHARMA/
TEVA PHARMA
5-Yr Chart
Click to enlarge
High Rs6453,029-   
Low Rs4702,631-   
Sales per share (Unadj.) Rs166.11,738.2-  
Earnings per share (Unadj.) Rs21.9108.6-  
Cash flow per share (Unadj.) Rs27.5249.1-  
Dividends per share (Unadj.) Rs4.0095.05-  
Dividend yield (eoy) %0.73.4 21.4%  
Book value per share (Unadj.) Rs117.81,930.8-  
Shares outstanding (eoy) m188.52848.00-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.6 206.2%   
Avg P/E ratio x25.526.1 97.7%  
P/CF ratio (eoy) x20.311.4 178.5%  
Price / Book Value ratio x4.71.5 323.0%  
Dividend payout %18.387.5 20.9%   
Avg Mkt Cap Rs m105,0902,399,704 4.4%   
No. of employees `000NA44.9 0.0%   
Total wages/salary Rs m6,2280-   
Avg. sales/employee Rs ThNM32,795.3-  
Avg. wages/employee Rs ThNM0-  
Avg. net profit/employee Rs ThNM2,048.7-  
INCOME DATA
Net Sales Rs m31,3081,473,984 2.1%  
Other income Rs m700-   
Total revenues Rs m31,3781,473,984 2.1%   
Gross profit Rs m6,431403,651 1.6%  
Depreciation Rs m1,055119,144 0.9%   
Interest Rs m3428,951 0.1%   
Profit before tax Rs m5,413255,556 2.1%   
Minority Interest Rs m01,161 0.0%   
Prior Period Items Rs m-810-   
Extraordinary Inc (Exp) Rs m0-167,759 0.0%   
Tax Rs m1,204-3,120 -38.6%   
Profit after tax Rs m4,12892,079 4.5%  
Gross profit margin %20.527.4 75.0%  
Effective tax rate %22.2-1.2 -1,821.2%   
Net profit margin %13.26.2 211.1%  
BALANCE SHEET DATA
Current assets Rs m18,247995,523 1.8%   
Current liabilities Rs m11,235868,180 1.3%   
Net working cap to sales %22.48.6 259.3%  
Current ratio x1.61.1 141.6%  
Inventory Days Days8691 94.2%  
Debtors Days Days6196 64.0%  
Net fixed assets Rs m20,035481,436 4.2%   
Share capital Rs m3773,628 10.4%   
"Free" reserves Rs m21,8240-   
Net worth Rs m22,2011,637,316 1.4%   
Long term debt Rs m5,000753,681 0.7%   
Total assets Rs m39,4113,368,525 1.2%  
Interest coverage x160.29.8 1,630.1%   
Debt to equity ratio x0.20.5 48.9%  
Sales to assets ratio x0.80.4 181.5%   
Return on assets %10.63.6 293.9%  
Return on equity %18.65.6 330.6%  
Return on capital %19.74.9 400.0%  
Exports to sales %46.40-   
Imports to sales %10.50-   
Net fx Rs m7,6960-   
CASH FLOW
From Operations Rs m3,124234,877 1.3%  
From Investments Rs m-8,844-83,226 10.6%  
From Financial Activity Rs m5,026-281,750 -1.8%  
Net Cashflow Rs m-693-130,100 0.5%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for TEVA PHARMA (Israel) is United States Dollars. All data has been converted at 72.56 Rs / USD

Compare ALEMBIC PHARMA With: MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  

Compare ALEMBIC PHARMA With: WYETH LTD  STERLING BIOTECH  NOVARTIS  TORRENT PHARMA  ALEMBIC LTD  



Today's Market

Sensex Ends 331 Points Higher; Oil & Gas Stocks Witness Buying(Closing)

After opening on a negative note, share markets in India witnessed buying interest during closing hours and ended the day on a positive note.

Related Views On News

ALEMBIC PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 61.0% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, ALEMBIC PHARMA has posted a net profit of Rs 2 bn (up 61.0% YoY). Sales on the other hand came in at Rs 11 bn (up 42.8% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

ALEMBIC PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 42.6% (Quarterly Result Update)

Jul 30, 2018 | Updated on Jul 30, 2018

For the quarter ended June 2018, ALEMBIC PHARMA has posted a net profit of Rs 904 m (up 42.6% YoY). Sales on the other hand came in at Rs 9 bn (up 33.1% YoY). Read on for a complete analysis of ALEMBIC PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

3 Big Money Makers to Round Out Your 2018 Portfolio(Profit Hunter)

Oct 31, 2018

The market is offering many strong opportunities in the small cap space right now. Don't miss out. This is the time to get rich.

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

Insider Buying: These Owner Operators Are Taking Advantage of the Correction(Chart Of The Day)

Nov 2, 2018

We believe insider buying is one of the strongest smart money indicators.

Are You Among The 35% Parents Who Will Not Be Able To Finance Their Child's Future?(Outside View)

Nov 1, 2018

PersonalFN explains the importance of being prepared for your child's future.

Are Fund Houses Opening Up Their NFO Factories Again?(Outside View)

Nov 2, 2018

PersonalFN sheds light on FY 2018-19 so far, the mutual fund industry has collectively launched 84 New Fund Offers (NFOs), of which some are still open for subscription.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALEMBIC PHARMA SHARE PRICE


Nov 13, 2018 (Close)

TRACK ALEMBIC PHARMA

  • Track your investment in ALEMBIC PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALEMBIC PHARMA

ALEMBIC PHARMA 8-QTR ANALYSIS

COMPARE ALEMBIC PHARMA WITH

MARKET STATS